[안구건조증(Dry Eye Sydrome) 치료제 신약 임상 IND 제출 관련]
작성일
2014-12-30
지트리비앤티, 안구건조증 임상.. 1.2조원 시장 잡는다
(국내 기사 본문보기 아래 클릭)
http://www.mt.co.kr/view/mtview.php?type=1&no=2014122612442966876&outlink=1
RegeneRx Partner Submits Pharse IIB/III IND to Korean Health Authority for RGN-259 for the Treatment of Dry Eye Syndrome
(해외 기사 본문보기 아래 클릭)
http://www.prnewswire.com/news-releases/regenerx-partner-submits-phase-iibiii-ind-to-korean-health-authority-for-rgn-259-for-the-treatment-of-dry-eye-syndrome-300014156.html
(국내 기사 본문보기 아래 클릭)
http://www.mt.co.kr/view/mtview.php?type=1&no=2014122612442966876&outlink=1
RegeneRx Partner Submits Pharse IIB/III IND to Korean Health Authority for RGN-259 for the Treatment of Dry Eye Syndrome
(해외 기사 본문보기 아래 클릭)
http://www.prnewswire.com/news-releases/regenerx-partner-submits-phase-iibiii-ind-to-korean-health-authority-for-rgn-259-for-the-treatment-of-dry-eye-syndrome-300014156.html